Skip to main content
OpenTrials
Completed

NCT Number: NCT05865626

Evaluation of the VOT Among Tuberculosis Patients From Lambaréné

This pilot study aimed to assess the feasibility of using an instant messenger to monitor drug intake in tuberculosis patients and to assess cash incentive to improve adherence to drug intake

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre de recherches médicales de Lambaréné

Lambaréné, 242, Gabon

About this study

At the initial visit, the inclusion criteria are cross-checked, the subject is informed of the study procedures, and an informed consent form is signed by subjects willing to participate.

For the participants from the intervention group, the research team will provide a smartphone with the WhatsApp application to each participant. At the initial visit, the research team will explain to the participants how to use the phone and the instant messenger application for the study. Briefly, the subject is filmed while taking the drug. This can be via a "selfie" or by a family member. The video is then sent to the study phone contact.

Once the video is received by an investigator, a message will be sent back to the participant's mobile phone acknowledging receipt of the video. An investigator trained on the DOT protocol, will review the video clips to assess if the drug was taken correctly or not. A daily log is filled in to keep track of drug intake for each participant.

Participants from both the control and intervention group are seen once per month in person for follow-ups and getting new drugs. At these time points information on drug intake is gathered.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Older than 18 years

  • Signed informed consent form
  • Living in an area with mobile phone coverage
  • Have at least 3 months of treatment remaining

Exclusion criteria

  • Not being able to use a smartphone and unlikely to learn how to

Treatment and study plan

VOT with and without cash incentive

Other

Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination

Other names: VOT

Primary outcomes

  1. feasibility assessment

    Time frame: at the end of study (2 years)

    proportion of participants in the intervention groups who regularly send the videos throughout the follow-up.

Secondary outcomes

  1. adherence to the VOT

    Time frame: at the end of study (2 years)

    number of videos received compared to the expected number of videos

  2. effect of cash incentives on adherence to the VOT

    Time frame: at the end of study (2 years)

    comparison of the proportion of videos received during the follow-up phase without financial motivation and the proportion of videos received during the follow-up phase with financial motivation.

Sponsors and collaborators

Lead sponsor

Centre de Recherche Médicale de Lambaréné

Other

Registry information

Official study title

A Pilot Study to Evaluate Video Observed Treatment Among Tuberculosis Patients From Lambaréné Using an Instant Messenger Application

Acronym: dotsapp

Important dates

Study start
2018
Primary completion
2020
Study completion
2022
First posted
May 19, 2023
Registry last updated
May 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.